SYNERGY: A Phase 1b/2 Study of Nenocorilant, a Selective Glucocorticoid Receptor Antagonist, Plus Nivolumab in Patients With Advanced Solid Malignancies

Presented: American Society of Clinical Oncology Annual Meeting, 30 May 2026, Chicago, IL

Presenter: Omid Hamid, MD

Scientific journal publications or scientific congress presentations may include information regarding investigational products or uses.